362
Renal denervation (RDN), 7, 152, 159, 160
baroreflex sensitivity, 317
BAT, 317
CKD, 314
Renal dysfunction, 140
Renal events, 60, 67, 68, 72
Renal ischemia, 161
Renal mechanosensory nerves, 94
Renal resistive index, 142
Renal sympathetic nerve activity
(RSNA)
adrenergic innervation, 150
α-adrenergic receptors, 150
angiotensin II and aldosterone, 151
electrical stimulation, 151
juxtaglomerular apparatus, 150
macula densa, 151
nephron, 150
PRA, 152
RAS, 152
renin secretion, 151
renin-suppressive factors, 152
sodium reabsorption, 151
Renal sympathetic nerves, 308
Renalase, 133
Renin angiotensin aldosterone system
(RAAS), 261
Renin–angiotensin-aldosterone system
(RAAS), 18, 19, 84, 150, 161,
174, 324
aldosteronism, 98
angiotensin receptors, 100
angiotensin-aldosterone escape pathway,
96–98
AT1R, 103
BMP system, 98
blockers, 142
chymase, 100
estrogens, 104
intracellular, 101
kallikrein-kinin system, 102
mineralocorticoid receptors, 98
oxidative stress, 98
pathophysiological dynamics, 104
pathophysiological functions, 101
plasma aldosterone, 99
plasma angiotensin 1–7, 103
PRR knockout, 100
renin and prorenin, 99–100
Renin-angiotensin system (RAS), 283
Renin-secreting granular cells, 150
Renocardiac syndrome, 27
Renoparenchymal disease, 34, 35
Renovascular hypertension, 14, 18, 19
Resistant hypertension (RH/RHT/RHTN), 45,
48, 59, 316
ABPM, 344
ACEIs, 289
ACEIs and ARBs, 289
active BP-lowering treatments, 72
adverse impact, 9
algorithm, 229
algorithmic approach, 85, 86
alpha-adrenergic blockers, 295
ambiguity, 77
antidepressant properties, 3
anti-hypertensives, 252
medication, 237
trials, 1
BBs, 294
BIS, 291
blood pressure, 1–3
bone marrow, 95
cardiovascular morbidity and mortality, 77
cardiovascular risk factor, 1
carotidian baroreflex, 93
CCBs, 292
characterization, 89
chemoreceptors, 93
chronic kidney disease, 348
chronotherapy, 251
CKD, 160, 249, 288–296
classification and causes, 60
clonidine, 287
cost-effectiveness, 249–251
definition, 2–5, 61, 83, 186–188, 219, 286
in developing countries, 244–247
device therapy, 251, 252
diabetic mellitus, 2
diabetic nephropathy and proteinuria, 260
diagnosis, 189, 190
dietary sodium intake, 220
diuretics, 291–292
dopamine, 104
ENaC, 106
epidemiology, 188, 260
ESC classification, 90
ESH/ESC guidelines, 294
etiology, 188, 189
evaluation, 82–85
factors, 262
fourth-line therapy, 222
further research, 9
GABAA receptors, 96
genetic mutations, 108
genetic profiling, 112
GP, 348
HCTZ, 249, 287Index